lifesciencesweden.se6d
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is ...
lifesciencesweden.se6d
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on ...
lifesciencesweden.se7d
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
The Swedish national life science strategy was launched in December 2019, and it has now been updated with a new government ...
lifesciencesweden.se13d
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
- Automation of complex in vitro model generation and quantification at scale - Brightfield and fluorescent imaging ...
lifesciencesweden.se3d
Unmatched performance and flexibility in its class
With its sensor flexibility, advanced technology and high accuracy, the new ZEISS SPECTRUM family offers the right solution for a multitude of measurement tasks. Optical scanning is now possible ...
lifesciencesweden.se4d
Webinar: Support Trial Patients Transitioning to the Commercial Space
Are you a pharmaceutical or biotech manufacturer preparing to commercialize a drug and wondering how to support your Phase III clinical trial patients post approval? In today’s complex access and ...
lifesciencesweden.se13d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.